$SNOA
Sonoma Pharmaceuticals, Inc. Stock $snoa

$snoa Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000168316824004275 Filed on June 17, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2024
Revenue	$3.391M	$3.439M	$12.74M
YoY Change	-1.05%	14.1%	-4.05%
Cost Of Revenue	$2.085M	$2.348M	$7.990M
YoY Change	-6.21%	9.82%	-9.15%
Gross Profit	$1.306M	$1.091M	$4.745M
YoY Change	8.47%	24.54%	5.99%
Gross Profit Margin	38.51%	31.72%	37.26%
Selling, General & Admin	$2.009M	$2.091M	$7.575M
YoY Change	-5.19%	15.52%	-14.31%
% of Gross Profit	153.83%	191.66%	159.64%
Research & Development	$470.0K	$409.0K	$1.871M
YoY Change	44.62%	103.48%	803.86%
% of Gross Profit	35.99%	37.49%	39.43%
Depreciation & Amortization	$39.00K	$41.00K	$176.0K
YoY Change	-13.33%	20.59%	40.8%
% of Gross Profit	2.99%	3.76%	3.71%
Operating Expenses	$2.479M	$2.500M	$9.446M
YoY Change	1.43%	24.32%	4.41%
Operating Profit	-$1.173M	-$1.409M	-$4.701M
YoY Change	-5.4%	24.14%	2.87%
Interest Expense			-$825.0K
YoY Change			-5256.25%
% of Operating Profit
Other Income/Expense, Net	$176.0K	$50.00K	$495.0K
YoY Change	-183.41%	-116.45%	-178.45%
Pretax Income	-$997.0K	-$1.359M	-$5.031M
YoY Change	-31.29%	-5.56%	-2.95%
Income Tax	$146.0K	-$292.0K	-$196.0K
% Of Pretax Income
Net Earnings	-$1.143M	-$1.067M	-$4.835M
YoY Change	-19.39%	-18.43%	-6.13%
Net Earnings / Revenue	-33.71%	-31.03%	-37.97%
Basic Earnings Per Share	-$0.07		-$0.53
Diluted Earnings Per Share	-$0.07	-$0.07	-$0.53
COMMON SHARES
Basic Shares Outstanding	18.77M shares	15.61M shares	9.090M shares
Diluted Shares Outstanding	17.03M shares		9.090M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.589M	$3.128M	$3.128M
YoY Change	-26.95%	-18.12%	-18.12%
Cash & Equivalents	$2.589M	$3.128M	$3.128M
Short-Term Investments
Other Short-Term Assets	$3.433M	$3.803M	$707.0K
YoY Change	-29.57%	-16.38%	0.57%
Inventory	$2.658M	$2.719M	$2.719M
Prepaid Expenses
Receivables	$3.247M	$2.898M	$2.898M
Other Receivables	$0.00	$0.00	$3.096M
Total Short-Term Assets	$11.93M	$12.55M	$12.55M
YoY Change	-12.22%	-9.06%	-9.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$302.0K	$365.0K	$651.0K
YoY Change	-37.73%	-25.2%	-28.15%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$61.00K	$66.00K	$1.541M
YoY Change	-20.78%	-9.59%	0.92%
Total Long-Term Assets	$1.746M	$2.192M	$2.192M
YoY Change	-24.28%	-9.91%	-9.91%
TOTAL ASSETS
Total Short-Term Assets	$11.93M	$12.55M	$12.55M
Total Long-Term Assets	$1.746M	$2.192M	$2.192M
Total Assets	$13.67M	$14.74M	$14.74M
YoY Change	-13.97%	-9.19%	-9.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$751.0K	$607.0K	$607.0K
YoY Change	-31.1%	-27.82%	-27.82%
Accrued Expenses	$2.383M	$2.311M	$1.617M
YoY Change	-4.22%	1.14%	-5.93%
Deferred Revenue
YoY Change
Short-Term Debt	$204.0K	$323.0K	$323.0K
YoY Change	-32.23%	-25.06%	-25.06%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.751M	$3.719M	$3.719M
YoY Change	-7.18%	0.05%	0.05%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$4.947M	$4.884M	$4.884M
YoY Change	7.31%	7.65%	7.65%
Total Long-Term Liabilities	$4.947M	$4.884M	$4.884M
YoY Change	7.31%	7.65%	7.65%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.751M	$3.719M	$3.719M
Total Long-Term Liabilities	$4.947M	$4.884M	$4.884M
Total Liabilities	$8.698M	$8.603M	$8.603M
YoY Change	0.54%	4.23%	4.23%
SHAREHOLDERS EQUITY
Retained Earnings	-$195.5M	-$194.3M
YoY Change	2.39%	2.55%
Common Stock	$204.1M	$203.2M
YoY Change	1.49%	1.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.975M	$6.137M	$6.137M
YoY Change
Total Liabilities & Shareholders Equity	$13.67M	$14.74M	$14.74M
YoY Change	-13.97%	-9.19%	-9.19%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2024
OPERATING ACTIVITIES
Net Income	-$1.143M	-$1.067M	-$4.835M
YoY Change	-19.39%	-18.43%	-6.13%
Depreciation, Depletion And Amortization	$39.00K	$41.00K	$176.0K
YoY Change	-13.33%	20.59%	40.8%
Cash From Operating Activities	-$912.0K	$152.0K	-$2.398M
YoY Change	324.19%	-106.23%	-61.02%
INVESTING ACTIVITIES
Capital Expenditures	$5.000K	-$3.000K	$17.00K
YoY Change	-70.59%	-101.58%	-93.68%
Acquisitions
YoY Change
Other Investing Activities		$15.00K	$15.00K
YoY Change		-86.11%	36.36%
Cash From Investing Activities	-$5.000K	$18.00K	-$2.000K
YoY Change	-70.59%	-121.95%	-99.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$1.784M
YoY Change			-37.8%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$636.0K	622.0K	$1.676M
YoY Change	-571.11%	-81.55%	-32.66%
NET CHANGE
Cash From Operating Activities	-$912.0K	152.0K	-$2.398M
Cash From Investing Activities	-$5.000K	18.00K	-$2.000K
Cash From Financing Activities	$636.0K	622.0K	$1.676M
Net Change In Cash	-$539.0K	792.0K	-$692.0K
YoY Change	95.29%	-6.71%	-80.65%
FREE CASH FLOW
Cash From Operating Activities	-$912.0K	$152.0K	-$2.398M
Capital Expenditures	$5.000K	-$3.000K	$17.00K
Free Cash Flow	-$917.0K	$155.0K	-$2.415M
YoY Change	295.26%	-105.89%	-62.39%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001367083
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024	SNOA	Adjustment To Correct Par Value AdjustmentToCorrectParValue		usd
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2024	dei	Trading Symbol TradingSymbol	SNOA
CY2024	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Public Float EntityPublicFloat	3797950	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	18773635	shares
CY2024	dei	Auditor Firm AuditorFirmId	215
CY2024	dei	Auditor Name AuditorName	Frazier & Deeter, LLC
CY2024	dei	Auditor Location AuditorLocation	Tampa, Florida
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3128000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3820000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2898000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2572000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	2719000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	2858000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3541000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4308000	usd
CY2024Q1	SNOA	Deferred Consideration Net Current DeferredConsiderationNetCurrent	262000	usd
CY2023Q1	SNOA	Deferred Consideration Net Current DeferredConsiderationNetCurrent	240000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	12548000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	13798000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	365000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	488000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	286000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	418000	usd
CY2024Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1145000	usd
CY2023Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	949000	usd
CY2024Q1	SNOA	Deferred Consideration Net Noncurrent DeferredConsiderationNetNoncurrent	330000	usd
CY2023Q1	SNOA	Deferred Consideration Net Noncurrent DeferredConsiderationNetNoncurrent	505000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	66000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	73000	usd
CY2024Q1	us-gaap	Assets Assets	14740000	usd
CY2023Q1	us-gaap	Assets Assets	16231000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	607000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	841000	usd
CY2024Q1	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	2113000	usd
CY2023Q1	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	2029000	usd
CY2024Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	478000	usd
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	160000	usd
CY2024Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	323000	usd
CY2023Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	431000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	198000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	256000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3719000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3717000	usd
CY2024Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	87000	usd
CY2023Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	140000	usd
CY2024Q1	SNOA	Withholding Tax Payable WithholdingTaxPayable	4710000	usd
CY2023Q1	SNOA	Withholding Tax Payable WithholdingTaxPayable	4235000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	87000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	162000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	8603000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	8254000	usd
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	24000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	24000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15607433	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15607433	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4933550	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4933550	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	203207000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	200904000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-194349000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-189514000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2723000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3418000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	6137000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	7977000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14740000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	125000	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	516000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	669000	usd
CY2024	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	109000	usd
CY2023	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	37000	usd
CY2024	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-161000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16231000	usd
CY2024	us-gaap	Revenues Revenues	12735000	usd
CY2023	us-gaap	Revenues Revenues	13272000	usd
CY2024	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7990000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8795000	usd
CY2024	us-gaap	Gross Profit GrossProfit	4745000	usd
CY2023	us-gaap	Gross Profit GrossProfit	4477000	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1871000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	207000	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-4701000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-4570000	usd
CY2024	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-330000	usd
CY2023	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-614000	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5031000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5184000	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-196000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-33000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-4835000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5151000	usd
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.53
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.53
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.52
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.52
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9090000	shares
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9090000	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3394000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3394000	shares
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-4835000	usd
CY2024	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	695000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	894000	usd
CY2024	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-4140000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-4257000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	8697000	usd
CY2023	SNOA	Proceeds From Atthemarket Sale Of Common Stock Net Of Offering Expenses ProceedsFromAtthemarketSaleOfCommonStockNetOfOfferingExpenses	2868000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	649000	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	20000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	894000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	7977000	usd
CY2024	SNOA	Proceeds From Sale Of Common Stock Net Of Offering Expenses ProceedsFromSaleOfCommonStockNetOfOfferingExpenses	1446000	usd
CY2024	SNOA	Proceeds From Atthemarket Sale Of Common Stock Net Of Offering Expenses ProceedsFromAtthemarketSaleOfCommonStockNetOfOfferingExpenses	338000	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	255000	usd
CY2024	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	261000	usd
CY2024	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	695000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-4835000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	6137000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-4835000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5151000	usd
CY2024	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	176000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-173000	usd
CY2024	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-0	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	1000	usd
CY2024	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	230000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4000	usd
CY2024	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-184000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-0	usd
CY2024	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1107000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	306000	usd
CY2024	SNOA	Increase Decrease In Deferred Consideration Net Of Discount IncreaseDecreaseInDeferredConsiderationNetOfDiscount	222000	usd
CY2023	SNOA	Increase Decrease In Deferred Consideration Net Of Discount IncreaseDecreaseInDeferredConsiderationNetOfDiscount	190000	usd
CY2024	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-278000	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-864000	usd
CY2024	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	19000	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	127000	usd
CY2024	SNOA	Increase Decrease In Withholding Tax Payable IncreaseDecreaseInWithholdingTaxPayable	475000	usd
CY2023	SNOA	Increase Decrease In Withholding Tax Payable IncreaseDecreaseInWithholdingTaxPayable	396000	usd
CY2024	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-161000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-173000	usd
CY2024	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	355000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1296000	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2398000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6152000	usd
CY2024	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	17000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	269000	usd
CY2024	us-gaap	Proceeds From Other Deposits ProceedsFromOtherDeposits	15000	usd
CY2023	us-gaap	Proceeds From Other Deposits ProceedsFromOtherDeposits	11000	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-258000	usd
CY2024	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1784000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2868000	usd
CY2024	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	-0	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	120000	usd
CY2024	us-gaap	Repayments Of Other Short Term Debt RepaymentsOfOtherShortTermDebt	481000	usd
CY2023	us-gaap	Repayments Of Other Short Term Debt RepaymentsOfOtherShortTermDebt	774000	usd
CY2024	SNOA	Insurance Premiums Financed From Financing Activities InsurancePremiumsFinancedFromFinancingActivities	-373000	usd
CY2023	SNOA	Insurance Premiums Financed From Financing Activities InsurancePremiumsFinancedFromFinancingActivities	-515000	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1676000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2489000	usd
CY2024	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	345000	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-692000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3576000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3820000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7396000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3128000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3820000	usd
CY2024	us-gaap	Interest Paid Net InterestPaidNet	22000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	17000	usd
CY2024	SNOA	Insurance Premiums Financed InsurancePremiumsFinanced	373000	usd
CY2023	SNOA	Insurance Premiums Financed InsurancePremiumsFinanced	515000	usd
CY2023	us-gaap	Marketing Expense MarketingExpense	156000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-4835000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5151000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-194349000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-189514000	usd
CY2024Q1	SNOA	Working Capital WorkingCapital	8829000	usd
CY2023Q1	SNOA	Working Capital WorkingCapital	10081000	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2398000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6152000	usd
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_844_eus-gaap--UseOfEstimates_zRtESMcoyhs4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86D_zkjpe65EBW6">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include reserves and write-downs related to receivables and inventories, the valuation allowance relating to the Company’s deferred tax assets, valuation of equity and the estimated amortization periods of upfront product licensing fees received from customers. Periodically, the Company evaluates and adjusts estimates accordingly.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zHqUTTmmgN56" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86C_zzfkkAqt1ZJi">Concentration of Credit Risk and Major Customers</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash, cash equivalents and accounts receivable. Cash and cash equivalents are maintained in financial institutions in the United States, Mexico and the Netherlands. The Company is exposed to credit risk in the event of default by these financial institutions for amounts in excess of the Federal Deposit Insurance Corporation insured limits. Cash and cash equivalents held in foreign banks are intentionally kept at minimal levels, and therefore have minimal credit risk associated with them. We currently have $1,185,000 of deposits above federally insured limits.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table shows major customers revenues as a percentage of net revenue:</p> <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zTHPeEcIYpO4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8BA_zr2rxZ65MvM5" style="display: none">Schedule of concentration of risk</span></td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Customer A</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230401__20240331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zRhdLssxhYel" title="Concentration risk, percentage">17</span>%</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zw6hpGerZZQg" title="Concentration risk, percentage">11</span>%</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Customer B</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230401__20240331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zg7fHPw6KXF3" title="Concentration risk, percentage">15</span>%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zv3okp4XY8sc" title="Concentration risk, percentage">16</span>%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Customer C</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230401__20240331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLFhHHvVVxp7" title="Concentration risk, percentage">14</span>%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zMOrTzcnwbA3" title="Concentration risk, percentage">18</span>%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Customer D</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_ecustom--ConcentrationRiskPercentage2_c20230401__20240331__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_fKg_____zsrQHq1XtqUa" style="font-size: 10pt"><b style="display: none">–</b></span><span style="font-size: 10pt">%</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_ecustom--ConcentrationRiskPercentage2_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_fKg_____zFr2YCvfU2W2"><b style="display: none">–</b></span><span style="font-size: 10pt">%</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table shows major customers accounts receivable balances as a percentage of net accounts receivables:</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Customer A</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_ecustom--ConcentrationRiskPercentage2_c20230401__20240331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_fKg_____zZD1obBPZR74"><b style="display: none">–</b></span><span style="font-size: 10pt">%</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_ecustom--ConcentrationRiskPercentage2_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_fKg_____zXHzbjWU54Kj"><b style="display: none">–</b></span><span style="font-size: 10pt">%</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left">Customer B</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230401__20240331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zkWwThahmJ6e" title="Concentration risk, percentage">13</span>%</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zxv5eho0rCx3" title="Concentration risk, percentage">22</span>%</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Customer C</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_ecustom--ConcentrationRiskPercentage2_c20230401__20240331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_fKg_____zVtSh4eDU4i6"><b style="display: none">–</b></span><span style="font-size: 10pt">%</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_ecustom--ConcentrationRiskPercentage2_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_fKg_____zPbZ7Uy0NfL4"><b style="display: none">–</b></span><span style="font-size: 10pt">%</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Customer D</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230401__20240331__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zZrtx9Shv3yd" title="Concentration risk, percentage">17</span>%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zRN2MHrFURe3" title="Concentration risk, percentage">21</span>%</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AB_zXvFwONGiZY1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td id="xdx_F0D_zDtLlVisD6Pb" style="text-align: left; width: 2%">*</td> <td id="xdx_F1D_zR8nH3B7XpTk" style="text-align: left; width: 98%">Represents less than 10%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2024Q1	SNOA	Allowance For Sales Discounts Rebates Distributor Fees And Returns AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns	27000	usd
CY2023Q1	SNOA	Allowance For Sales Discounts Rebates Distributor Fees And Returns AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns	16000	usd
CY2024Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	296000	usd
CY2023Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	236000	usd
CY2024	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet	0	usd
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet	0	usd
CY2024	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1871000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	207000	usd
CY2024	us-gaap	Marketing Expense MarketingExpense	156000	usd
CY2024	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	695000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	894000	usd
CY2024	us-gaap	Foreign Currency Transaction Loss Before Tax ForeignCurrencyTransactionLossBeforeTax	825000	usd
CY2023	us-gaap	Foreign Currency Transaction Loss Before Tax ForeignCurrencyTransactionLossBeforeTax	692000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3541000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4308000	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2723000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3418000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-4835000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5151000	usd
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9090000	shares
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9090000	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3394000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3394000	shares
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.53
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.53
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.52
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.52
CY2024	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1033000	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	715000	shares
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1419000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1463000	usd
CY2024Q1	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	2925000	usd
CY2023Q1	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	2588000	usd
CY2024Q1	SNOA	Discounts Rebates Distributor Fees And Returns DiscountsRebatesDistributorFeesAndReturns	27000	usd
CY2023Q1	SNOA	Discounts Rebates Distributor Fees And Returns DiscountsRebatesDistributorFeesAndReturns	16000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2898000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2572000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	694000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	566000	usd
CY2024Q1	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	2113000	usd
CY2023Q1	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	2029000	usd
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	24000000	shares
CY2024Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1802000	usd
CY2023Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1764000	usd
CY2024Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1213000	usd
CY2023Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1330000	usd
CY2024Q1	us-gaap	Inventory Gross InventoryGross	3015000	usd
CY2023Q1	us-gaap	Inventory Gross InventoryGross	3094000	usd
CY2024Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	296000	usd
CY2023Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	236000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	2719000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	2858000	usd
CY2024Q1	us-gaap	Prepaid Insurance PrepaidInsurance	340000	usd
CY2023Q1	us-gaap	Prepaid Insurance PrepaidInsurance	438000	usd
CY2024Q1	us-gaap	Prepaid Taxes PrepaidTaxes	3096000	usd
CY2023Q1	us-gaap	Prepaid Taxes PrepaidTaxes	3845000	usd
CY2024Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	105000	usd
CY2023Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	25000	usd
CY2024Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1776000	usd
CY2023Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1624000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	236000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	202000	usd
CY2024Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	128000	usd
CY2023Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	122000	usd
CY2024Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	605000	usd
CY2023Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	554000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2745000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2502000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2380000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2014000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	365000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	488000	usd
CY2024	us-gaap	Depreciation And Amortization DepreciationAndAmortization	176000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	125000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	286000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	418000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	198000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	256000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	87000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	162000	usd
CY2024	us-gaap	Operating Lease Cost OperatingLeaseCost	380000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	385000	usd
CY2024	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	161000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	173000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P19M21D
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P19M12D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.06	pure
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.06	pure
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	227000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	68000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	15000	usd
CY2024Q1	SNOA	Lessee Operating Lease Liability Payments Due After Year Three LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree	9000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	319000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	34000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	285000	usd
CY2024	us-gaap	Officers Compensation OfficersCompensation	586000	usd
CY2024Q1	SNOA	Potential Severance Payments PotentialSeverancePayments	1300000	usd
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.19
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.09
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M21D
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0387	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0392	pure
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9840	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.1088	pure
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.15
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.92
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	516000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	669000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1032999	shares
CY2024	us-gaap	Profit Loss ProfitLoss	-4923000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-5182000	usd
CY2024	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2000	usd
CY2024	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-198000	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-35000	usd
CY2024	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-196000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-33000	usd
CY2024	SNOA	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rates EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates	0.210	pure
CY2023	SNOA	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rates EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates	0.210	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.002	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.008	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.079	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.065	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.058	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.075	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.201	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.161	pure
CY2024	SNOA	Trueups Of State Deferred Assets TrueupsOfStateDeferredAssets	-0.015	pure
CY2023	SNOA	Trueups Of State Deferred Assets TrueupsOfStateDeferredAssets	0.013	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.017	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.060	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.023	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.054	pure
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.040	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.006	pure
CY2024Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	28692000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	28558000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1796000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1800000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	913000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	739000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	659000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	795000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	52000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	20000	usd
CY2024Q1	SNOA	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	22000	usd
CY2023Q1	SNOA	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	24000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	32134000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	31936000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	30836000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	30809000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1298000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1127000	usd
CY2024Q1	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	10000	usd
CY2023Q1	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	16000	usd
CY2024Q1	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	121000	usd
CY2023Q1	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	138000	usd
CY2024Q1	SNOA	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	22000	usd
CY2023Q1	SNOA	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	24000	usd
CY2024Q1	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	153000	usd
CY2023Q1	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	178000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	1145000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	949000	usd
CY2024	us-gaap	Pension And Other Postretirement Benefit Contributions PensionAndOtherPostretirementBenefitContributions	82000	usd
CY2023	us-gaap	Pension And Other Postretirement Benefit Contributions PensionAndOtherPostretirementBenefitContributions	101000	usd
CY2024	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12735000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13272000	usd
CY2024	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12735000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13272000	usd
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001683168-24-004275-index-headers.html	Edgar Link	pending
0001683168-24-004275-index.html	Edgar Link	pending
0001683168-24-004275.txt	Edgar Link	pending
0001683168-24-004275-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_011.jpg	Edgar Link	pending
image_012.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
snoa-20240331.xsd	Edgar Link	pending
snoa-20240331_def.xml	Edgar Link	unprocessable
snoa-20240331_lab.xml	Edgar Link	unprocessable
snoa-20240331_pre.xml	Edgar Link	unprocessable
sonoma_ex0310.htm	Edgar Link	pending
sonoma_ex2301.htm	Edgar Link	pending
sonoma_ex3101.htm	Edgar Link	pending
sonoma_ex3102.htm	Edgar Link	pending
sonoma_ex3201.htm	Edgar Link	pending
sonoma_ex9700.htm	Edgar Link	pending
sonoma_i10k-033124.htm	Edgar Link	pending
sonoma_i10k-033124_htm.xml	Edgar Link	completed
snoa-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SNOA
Sonoma Pharmaceuticals, Inc. Stock $snoa

2024 Q2 Form 10-K Financial Statement

#000168316824004275 Filed on June 17, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SNOA Sonoma Pharmaceuticals, Inc. Stock $snoa

2024 Q2 Form 10-K Financial Statement

#000168316824004275 Filed on June 17, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SNOA
Sonoma Pharmaceuticals, Inc. Stock $snoa